Management of Acute Ischemic Stroke
Introduction to Management
- The American Heart Association recommends administering IV alteplase (0.9 mg/kg, maximum 90 mg) to eligible patients within 3 hours of symptom onset, with a target door-to-needle time under 60 minutes, and consider endovascular thrombectomy for large vessel occlusions within 6-24 hours based on imaging selection 1, 2, 3
Pre-Hospital Recognition and Transport
- EMS should use FAST (Face, Arms, Speech, Time) screening tools to rapidly identify stroke patients, as even a single abnormality has 72% probability of stroke 2, 3
- Pre-notify the receiving hospital immediately to activate stroke protocols and prepare the stroke team, imaging, and necessary resources before patient arrival 2, 3
- Document the exact time the patient was last known to be normal (last known well time), as this determines treatment eligibility, not when symptoms were discovered 1, 3
- Transport directly to comprehensive stroke centers capable of endovascular therapy when large vessel occlusion is suspected, rather than routing through primary stroke centers ("mothership" approach preferred over "drip-and-ship" when feasible) 4
Emergency Department Assessment
- Perform immediate non-contrast CT scan to rule out hemorrhage and identify early infarction signs 1, 2, 3
- Complete CT angiography immediately to identify large vessel occlusions and their location 2, 3
- Assess NIHSS score during parallel processing while imaging is being obtained 1, 4
IV Alteplase Administration
- Inclusion criteria for IV alteplase administration include clearly defined symptom onset within 3 hours, measurable neurologic deficit on NIHSS, age ≥18 years, and CT scan showing no hemorrhage 1, 2, 5
- Critical exclusion criteria for IV alteplase administration include blood pressure >185/110 mmHg, platelet count <100,000, INR >1.6 or PT >15 seconds, glucose <50 or >400 mg/dL, prior stroke or serious head injury within 3 months, major surgery within 14 days, history of intracranial hemorrhage, and rapidly improving or minor symptoms 1, 2, 5
- The dosing protocol for IV alteplase administration is 0.9 mg/kg (maximum 90 mg total), with 10% given as IV bolus over 1 minute and the remaining 90% infused over 60 minutes 1, 2, 3
Blood Pressure Management
- Before alteplase administration, blood pressure must be <185/110 mmHg, and labetalol, nicardipine, or clevidipine can be used to lower blood pressure if needed 1, 3
- During and after alteplase administration, blood pressure should be maintained at ≤180/105 mmHg, and monitored every 15 minutes during infusion and for 2 hours after, then every 30 minutes for 6 hours, and then hourly until 24 hours 1, 2, 3
Endovascular Thrombectomy
- Indications for endovascular thrombectomy include proximal anterior circulation large vessel occlusion (ICA, M1, proximal M2), with a standard window of within 6 hours of symptom onset and an extended window of up to 24 hours in selected patients with favorable CT perfusion or MRI diffusion/perfusion mismatch 2, 4, 6
- The optimal technique for endovascular thrombectomy is the BADDASS approach, which includes using a combined stent-retriever and aspiration technique, deploying the stent-retriever with two-thirds beyond the thrombus, and applying dual aspiration through a balloon guide catheter and distal access catheter during retrieval 2, 6
Post-Alteplase Monitoring and Complications
- Neurological monitoring should be performed every 15 minutes during and for 2 hours after infusion, every 30 minutes for the next 6 hours, and then hourly until 24 hours, with immediate stop of infusion and emergency head CT if severe headache, acute hypertension, nausea, vomiting, or neurological worsening occurs 1, 2, 3
- Symptomatic intracranial hemorrhage management includes stopping alteplase infusion, obtaining emergent non-contrast head CT, checking CBC, PT/INR, aPTT, fibrinogen, and type and cross-match, administering cryoprecipitate and tranexamic acid or ε-aminocaproic acid, and consulting hematology and neurosurgery 1, 2, 3
Physiological Parameter Management
- Temperature control includes monitoring temperature every 4 hours for the first 48 hours, treating fever >37.5°C with antipyretics, identifying and treating sources of hyperthermia, and avoiding hypothermia except in clinical trial contexts 2, 3
- Glucose management includes monitoring blood glucose regularly, treating hyperglycemia to maintain 140-180 mg/dL, and avoiding hypoglycemia with close monitoring 2, 3
Early Antiplatelet Therapy
- Aspirin 160-325 mg should be started within 24-48 hours after ruling out hemorrhage on follow-up imaging, and delayed for 24 hours if alteplase was given 2, 3
Stroke Unit Care and Early Rehabilitation
- All stroke patients should be admitted to a geographically defined stroke unit with specialized staff within 24 hours of arrival, and rehabilitation assessment should begin within 48 hours of admission 2
- Frequent, brief out-of-bed activity should be started within 24 hours if no contraindications, and swallowing, nutrition, and hydration status should be screened on the day of admission 2
Management of Cerebral Edema and Increased ICP
- Corticosteroids should not be used for cerebral edema, and osmotherapy and hyperventilation should be used for deteriorating patients 2
- Surgical decompression may be life-saving for large cerebellar infarctions with brainstem compression, and decompressive hemicraniectomy should be performed urgently for malignant MCA infarction before significant GCS decline or pupillary changes, ideally within 48 hours of onset 2, 3
Seizure Management
- New-onset seizures should be treated with short-acting medications, and prophylactic anticonvulsants should not be used 2
Common Pitfalls to Avoid
- Every 30-minute delay in recanalization decreases good functional outcome by 8-14%, and speed is critical 2
- Failure to obtain follow-up imaging at 24 hours before starting antiplatelets or anticoagulants increases hemorrhage risk, and inadequate blood pressure control before thrombolysis significantly increases symptomatic
Acute Ischemic Stroke – Imaging, Reperfusion, and Early Post‑Treatment Management
Initial Emergency Imaging
- All patients with suspected acute ischemic stroke should undergo emergent brain imaging (non‑contrast CT or MRI) before any reperfusion therapy, and the study must be interpreted within 45 minutes of emergency‑department arrival. 7
- A non‑contrast CT scan is adequate in the majority of cases to rule out intracranial hemorrhage (an absolute contraindication to thrombolysis) and to detect early ischemic changes. 7
- When mechanical thrombectomy is being considered, a CT‑angiography should be performed immediately, but it must not postpone the start of intravenous alteplase. 7
- Extensive early hypodensity involving more than one‑third of the middle‑cerebral‑artery territory on CT is an exclusion criterion for intravenous alteplase. 7
Blood‑Pressure Management Around Intravenous Alteplase
- Prior to alteplase administration, systolic/diastolic blood pressure must be < 185/110 mmHg; during and after infusion it should be maintained at ≤ 180/105 mmHg. 8
- Preferred agents for rapid blood‑pressure reduction before thrombolysis include:
- Labetalol 10–20 mg IV over 1–2 minutes (may repeat once).
- Nicardipine infusion starting at 5 mg/h, titrated by 2.5 mg/h every 5–15 minutes, max 15 mg/h.
- Clevidipine infusion 1–2 mg/h, doubled every 2–5 minutes, max 21 mg/h. All agents are recommended by the guideline. 8
- Blood‑pressure monitoring schedule: every 15 minutes during the alteplase infusion and for the subsequent 2 hours; every 30 minutes for the next 6 hours; then hourly up to 24 hours. 8
Endovascular Thrombectomy (Mechanical)
- Patients with proximal large‑vessel occlusion (e.g., internal carotid artery, M1 segment, or proximal M2 segment) should receive mechanical thrombectomy within 6 hours of symptom onset; the treatment window can be extended to 24 hours in selected patients who have favorable advanced imaging. 9
- Endovascular thrombectomy is indicated both for patients who have already received intravenous alteplase and for those who are ineligible for alteplase. 9
- When a patient qualifies for both intravenous alteplase and thrombectomy, alteplase should be started while the angiography suite is being prepared, so that the two therapies proceed in parallel without delay. 9
- Routine administration of alteplase is not recommended for patients who are on direct oral anticoagulants (DOACs). 9
Physiologic Parameter Management (Temperature & Glucose)
- Hyperthermia should be identified and treated promptly; sources of increased body temperature must be sought and managed. 8
- Blood glucose should be monitored regularly; hyperglycemia is to be treated to keep glucose levels between 140 and 180 mg/dL, and hypoglycemia should be avoided through vigilant monitoring. 8
Evidence‑Based Recommendations for Acute Ischemic Stroke Thrombolysis and Early Antiplatelet Therapy
Cerebral Microbleeds and IV Alteplase
- In patients with 1–10 cerebral microbleeds identified on prior MRI, administering IV alteplase is considered reasonable because the potential benefit outweighs the modest increase in hemorrhagic risk. 10
- In patients with more than 10 cerebral microbleeds, IV alteplase may still be reasonable only when the anticipated clinical benefit is substantial enough to justify the heightened risk of intracerebral hemorrhage. 10
Concurrent Acute Myocardial Infarction (MI) and Stroke
- When an acute MI occurs simultaneously with an acute ischemic stroke, the recommended approach is to give the standard cerebral‑ischemia dose of IV alteplase first, followed promptly by percutaneous coronary intervention (PCI) for the myocardial infarction. 10
Unruptured Intracranial Aneurysms and Thrombolysis
- For patients harboring an unruptured intracranial aneurysm smaller than 10 mm, IV alteplase is deemed reasonable.
- For giant aneurysms (≥10 mm), the risk‑benefit balance of alteplase is uncertain, and treatment decisions should be individualized. 10
Stroke Unit Admission and Outcomes
- Admission of acute ischemic stroke patients to a dedicated stroke unit within 24 hours of hospital arrival reduces mortality (odds ratio 0.76) and dependence (odds ratio 0.80) compared with care on a general medical ward. 11
Early Antiplatelet Therapy for Minor Stroke
- Initiating a combination of aspirin (160–325 mg) plus clopidogrel within 24 hours of symptom onset in patients with minor stroke (NIHSS < 4) is safe and lowers the risk of recurrent stroke at 90 days. 12
Aspirin Co‑administration with IV Alteplase
- Administering aspirin concurrently with IV alteplase during the acute thrombolytic window markedly increases the incidence of symptomatic intracranial hemorrhage (4.3% with aspirin vs 1.6% without). Therefore, aspirin should be withheld for at least 24 hours after alteplase infusion. 12
Guideline Recommendations for Posterior Cerebral Artery Infarct Management
Acute Reperfusion Therapy
IV alteplase dosing and time window – The American Heart Association/American Stroke Association (AHA/ASA) recommends administering alteplase 0.9 mg/kg (maximum 90 mg) to eligible patients with posterior cerebral artery (PCA) infarction within 3 hours of symptom onset; the window may be extended to 4.5–24 hours for posterior‑circulation strokes when recent evidence shows superior functional outcomes. Class I, Level A 13
Contraindications to alteplase – Patients should be excluded from thrombolysis if any of the following are present: systolic/diastolic BP > 185/110 mm Hg, platelet count < 100 × 10⁹/L, INR > 1.7, glucose < 50 mg/dL or > 400 mg/dL, extensive early CT hypodensity (> 1/3 of an MCA‑equivalent territory), stroke within the prior 3 months, prior intracranial hemorrhage, or major surgery within 14 days. Class I, Level A 13
Blood Pressure Management Around Alteplase
Pre‑thrombolysis BP reduction – Target a BP < 185/110 mm Hg using rapid‑acting agents (e.g., labetalol 10–20 mg IV bolus, nicardipine infusion starting at 5 mg/h titrated by 2.5 mg/h, or clevidipine 1–2 mg/h doubled every 2–5 min, max 21 mg/h). Class I, Level A 13
In‑treatment and post‑treatment BP targets – Maintain systolic/diastolic BP ≤ 180/105 mm Hg during and after alteplase infusion. Class I, Level A 13
BP monitoring schedule – Check BP every 15 minutes during the alteplase infusion and for 2 hours afterward, then every 30 minutes for the next 6 hours, and hourly until 24 hours post‑infusion. Class I, Level A 13
Endovascular Thrombectomy
- Indications for PCA occlusions – For proximal PCA occlusions with a substantial penumbral pattern on perfusion imaging, consider endovascular thrombectomy within 6–24 hours of onset, even though most guidelines focus on anterior circulation. Class IIa, Level B 14
Metabolic Management
- Glucose control – Maintain blood glucose between 140–180 mg/dL in the acute phase, with regular monitoring to avoid hypoglycemia. Class I, Level A 13
Secondary Prevention – Antiplatelet Therapy
Aspirin initiation – Start aspirin 160–325 mg within 24–48 hours after stroke onset; if alteplase was given, delay aspirin for 24 hours because concurrent use raises symptomatic intracerebral hemorrhage (ICH) risk from 1.6 % to 4.3 %. Class I, Level A [15][13]
Avoid early antiplatelet after thrombolysis – Do not administer any antiplatelet agent within 24 hours of alteplase to prevent a marked increase in symptomatic ICH. Class I, Level A 15